Mining millions of AI-predicted structures reveals an evolutionarily conserved protein that resembles a receptor family ...

NVO tumbled about 8% as its Capital Markets Day failed to convince investors despite plans for more than five “multi-blockbusters” by 2030. ・Viking’s injectable VK2735 produced up to 14.7% weight loss ...

Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Exicure (NASDAQ:XCUR) signed a MOU with GPCR Therapeutics aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR ...

Structure Therapeutics (GPCR) stock slides in reaction to trial data for the company's lead obesity candidates, ACCG-2671 and aleniglipron. Read more here.

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...

Scientists at St. Jude Children's Research Hospital and Columbia University/New York State Psychiatric Institute are studying G protein-coupled receptors (GPCRs), membrane proteins that are the target ...